Last reviewed · How we verify
NCT04207216
Use of Alternative Therapy in Psoriasis Vulgaris Patients
trial in Psoriasis Vulgaris in 1,618 participants. Completed in 1 July 2020.
1 July 2020
Quick facts
| Lead sponsor | Istanbul Medeniyet University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,618 |
| Start date | 1 January 2020 |
| Primary completion | 1 July 2020 |
| Estimated completion | 1 July 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →
Sponsor
Istanbul Medeniyet University
Who can join
Adults 18 to 90, any sex, with Psoriasis Vulgaris. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Psoriasis Vulgaris is a chronic, recurrent, inflammatory and hyperproliferative skin disease. Joint involvement is common along with skin involvement. However, metabolic diseases, such as cardiovascular diseases can be accompanied by many systemic diseases, chronic and repetitive due to the quality of life and psychological status of patients can affect. Today, although the treatment is repetitive, chronic and requires follow-up due to the disease patients can turn to alternative and complementary medicine techniques. In recent years, studies on alternative medicine and complementary therapies have been noted in the medical literature. These studies also include Case Reports related to psoriasis vulgaris. However, in our country, there is no study that tells us whether patients with psoriasis vulgaris apply these treatments or not and what the practitioners think about the success of the treatment. The aim of the study will be to clarify issues such as whether patients with Psoriasis Vulgaris apply alternative medicine and complementary therapies for their disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patient Use of Complementary and Alternative Medicine for Psoriasis Vulgaris and Factors Believed to Trigger the Disease: a Multicenter Cross-Sectional Study With 1621 Patients.
Kayıran MA, Karadağ AS, Topal İO, Emre S, et al · · 2022 · cited 3× · PMID 36534567 · DOI 10.5826/dpc.1204a190
Verify or expand the search:
- PubMed search for NCT04207216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriasis Vulgaris
Currently open trials in the same condition.
- NCT07426120 — Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III · Phase 3 · recruiting
- NCT07320872 — Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris · recruiting
- NCT06398106 — Proactive TDM Versus Standard Use of Biologics in Psoriasis · Phase 4 · recruiting
- NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting
- NCT04950218 — Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis · recruiting
Other Istanbul Medeniyet University trials
Trials by the same sponsor.
- NCT07478380 — Transcutaneous pO₂ Monitoring in PICU · recruiting
- NCT07368244 — Turkish Translation and Content Validity of the Nottwil Environmental Factors Inventory (NEFI) in Persons With Spinal Co · recruiting
- NCT07179731 — Comparison of the Effects of External Oblique Intercostal Plane Block, Subcostal Transverse Abdominis Plane Block, and T · NA · not yet recruiting
- NCT07241455 — Validity of the Children's Chelsea Critical Care Physical Assessment Tool (cCPAx-TR) in Turkish Pediatric Intensive Care · completed
- NCT07426497 — Osteopathic Manual Therapy vs Ganglion Impar Block for Chronic Coccydynia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04207216 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Medeniyet University
- Last refreshed: 11 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04207216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing